Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Theravance Biopharma (NASDAQ:TBPH) had its price target raised by analysts at BTIG Research from $25.00 to $40.00. They now have a "buy" rating on the stock.
Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at
Wall Stre
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 [Yahoo! Finance]
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025